மருத்துவ பரிசோதனைகளின் இதழ்
திறந்த அணுகல்

சுருக்கம்

Management of A COVID-19 Spike Protein based Vaccine which Inducing Blood Clots and Damage to ACE2 Expressing Cells-A Double-Edged Sword

Mahmoud Elkazzaz*, Yousry Abo-amer, Tamer Haydara

The interaction between various COVID-19 vaccines and our immune system's response to mediate protection or susceptibility to SARS-CoV-2 is in the very initial stages of understanding. Hundreds of 2019 Corona virus disease targeting vaccines are currently in progress, but success is unknown. Most of the vaccine candidates use a protein- based subunit (spike protein-based vaccine)-so, instead of using a complete pathogenic virus, they are built on a small component of it, such as a protein found in its outer shell. That protein is administered to patients in a high dose, with the aim of inducing a fast and strong reaction by the human immune system. Spike protein-based vaccines were granted emergency approval within a limited period of time and are now being rolled out. This type of vaccine provides our cells with signals to express a component of what is called the “COVID-19 spike protein.” Here, we use existing and emerging evidence to propose a testable hypothesis that Spike protein-based vaccines may initiate blood clots as the same as the action of COVID-19 spike protein by the strong interaction between Angiotensin- converting enzyme 2 (ACE2) expressed on platelets and the receptor binding domain of the spike protein generated by vaccination leading to initiating autoantibodies to platelets that mistakenly react and target human platelets leading to serious complication presented in platelet aggregation and blood clots.